Navigation Links
Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
Date:4/20/2011

st quarter of 2010. Sales of Nplate® (romiplostim) increased 33 percent to $65 million in the first quarter of 2011 versus $49 million in the first quarter of 2010. These increases were driven by an increase in worldwide demand.

Sales of Prolia® (denosumab) in the first quarter of 2011 were $27 million, building momentum with physicians, patients and payers in the U.S. and internationally.

U.S. sales of XGEVA™ (denosumab) were $42 million in the first full quarter following launch.

Operating Expense Analysis on an Adjusted Basis:Cost of Sales increased to 14.9 percent of sales in the first quarter of 2011 versus 14.3 percent of sales in the first quarter of 2010.  This increase was driven primarily by higher bulk material cost and the above noted Puerto Rico excise tax, offset partially by higher average net sales prices and lower royalties.  Excluding the $13 million impact of the excise tax, cost of sales would have been 14.6 percent of sales for the quarter.Research & Development (R&D) expenses increased 14 percent to $703 million in the first quarter of 2011 versus $617 million in the first quarter of 2010.  This reflected our strategic decision to invest in late stage clinical trials, including AMG 386 and AMG 479, and to augment support for marketed products.  R&D expenses also increased due to higher staff-related costs primarily in support of international expansion and discovery research.Selling, General & Administrative (SG&A) expenses increased 16 percent to $1,011 million in the first quarter of 2011 versus $873 million in the first quarter of 2010.  This comparison was impacted by certain expenses in the first quarter of 2011 that did not occur in the same period last year, including the U.S. Healthcare Reform Excise Fee of $39 million and promotional costs primarily due to the launches of Prolia and XGEVA.  This increase was also driven by higher ENBRE
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
2. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
3. Cepheid Reports 2011 First Quarter Results
4. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
5. Caliper Life Sciences First Quarter Results Conference Call Notice
6. Siemens Applauds First Health System Customers to Successfully Attest to Meaningful Use
7. Cardiogenesis Corporation to Report 2011 First Quarter Results on May 4th
8. PDL BioPharma to Announce First Quarter 2011 Financial Results on April 27, 2011
9. WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release
10. Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 2011
11. MiMedx Group, Inc. Announces Release Date for First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... TWi Pharmaceuticals, Inc. ("TWi") today announced ... with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals ... Inc. (individually and collectively, "Takeda") to settle and ... generic dexlansoprazole delayed release capsules for oral administration ... Abbreviated New Drug Application for TWi,s generic product ...
(Date:4/25/2015)... -- Hospira, Inc. (NYSE: HSP ... sprach heute auf der jährlichen Konferenz der Europäischen ... London über die Bedeutung von ... für Patienten. Das Unternehmen kündigte auch ... Titel „Why extrapolation is paramount to achieving ...
(Date:4/24/2015)... 24, 2015 Today, humanity takes a massive step ... and fat-free cronuts: 1-800 CONTACTS announces their new Apple Watch ... two taps. Two taps. New contacts. From your ... The app also features LensGauge which helps keep track of ... need to reorder. "Since our inception, we,ve been ...
Breaking Medicine Technology:TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2
(Date:4/27/2015)... Mirada, CA (PRWEB) April 27, 2015 ... minimally invasive treatments for nail fungi and infections. Onychomycosis, ... to affect up to 10% of adults in the ... fragility, and irregularity in thickness. , Healthpointe’s ... Institute , a branch dedicated to providing quality skincare ...
(Date:4/27/2015)... Miami, FL (PRWEB) April 27, 2015 ... policies from arresting nonviolent drug offenders to providing drug ... by Nepr on April 8th. Several states, ... cut state costs revolving incarceration. Texas has formed community ... populace. According to The Council of State Governments ...
(Date:4/27/2015)... April 27, 2015 Consumer Choice ... Service Providers in their respective sectors for Ottawa. We ... year’s winners; your dedication to superior service has resonated ... Canada, Consumer Choice Award gathers opinions, perceptions and expectations ... All winners have gone through a rigorous selection process ...
(Date:4/27/2015)... 2015 The Sanford J. Grossman Charitable ... Grossman, PhD, has committed $3 million to establish the ... Inflammatory Bowel Disease at the Icahn School of Medicine ... personalized medicine for treatment of Crohn’s disease, with the ... Crohn’s Disease, a chronic inflammatory disorder of the bowel ...
(Date:4/27/2015)... April 27, 2015 Final Cut Pro ... footage with ProTelestrator from Pixel Film Studios. A telestrator is ... sketch over a moving or still video image. Telestrators are ... analyze sports plays or incoming weather patterns. , After users ... then adjust the frame slider to control the speed of ...
Breaking Medicine News(10 mins):Health News:Southern California Healthpointe Clinics Now Treating Nail Fungus 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 3Health News:2015 Ottawa Consumer Choice Award-Winners 2Health News:2015 Ottawa Consumer Choice Award-Winners 3Health News:2015 Ottawa Consumer Choice Award-Winners 4Health News:2015 Ottawa Consumer Choice Award-Winners 5Health News:2015 Ottawa Consumer Choice Award-Winners 6Health News:2015 Ottawa Consumer Choice Award-Winners 7Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 2Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 3Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2
... has been discovered by researchers at Seoul National University. It ... highly expressed in lung cancer cells and also that patients ... study is published on March 31 in the open-access journal ... of the world,s most common cancers and a leading cause ...
... cancer organizations shows rates of death in the United States from ... and 2007. The findings come from the latest Annual Report to ... also finds that the overall rate of new cancer diagnoses for ... 1 percent per year for the same period. Edward J. ...
... from the University of Pittsburgh and Stanford University discovered ... role in the ability of one the world,s most ... possible role of similarly errant proteins in other diseases. ... the National Academy of Sciences ( PNAS ) ...
... the obesity epidemic, the National Institutes of Health is ... for NIH Obesity Research. More than one-third ... percent of the nation,s children are now obese, which ... including type 2 diabetes, heart disease, high blood pressure, ...
... a total of $383,000 for chronic obstructive pulmonary disease ... Institute (NHLBI), part of the National Institutes of Health, ... COPD Learn More Breathe Better campaign and will be ... The contract supports community-based public health efforts to ...
... continues to grow. Following the successful First International ... Second International Conference on Immune Tolerance will bring ... and insights into the mechanisms and treatment of ... inflammation and cancer. This Conference is supported by ...
Cached Medicine News:Health News:Pitt-Stanford research suggests aimless proteins crucial to disease 2Health News:New strategic plan for NIH obesity research seeks to curb epidemic 2Health News:NHLBI funds 9 organizations to improve awareness of COPD 2Health News:2nd International Conference on Immune Tolerance 2
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
... The VISULAS 690s is ... As the instrument of choice ... Visudyne clinical trials, Carl Zeiss ... legacy in laser manufacturing to ...
The SL 115 Classic Slit Lamp offers you high optical performance and convenient operation. It is not only the ideal instrument for all routine examinations and contact lens fitting, but is also excel...
Lens Loading and Folding for Multipiece & Single-Piece ACRYSOF Lens with Standard Forceps...
Medicine Products: